Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: Expression and prognostic importance of ten different markers

Tumor Biology

Volumn 32, Issue 3, 2011, Pages 451-459

  Koivisto Korander, Riitta ^a   Butzow, Ralf ^a   Koivisto, Anna Maija ^b   Leminen, Arto ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

ER ; Immunohistochemistry; PRA; Tumor markers; Uterine sarcoma

Indexed keywords

ANDROGEN RECEPTOR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DESMIN; ESTROGEN RECEPTOR ALPHA; HERMES ANTIGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR A; PROTEIN P53; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOSARCOMA; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIUM SARCOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; UTERUS SARCOMA; CHEMISTRY; ENDOMETRIUM TUMOR; FEMALE; MIDDLE AGED; MORTALITY; SURVIVAL RATE; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; PROGNOSIS; RECEPTORS, PROGESTERONE; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 79960593150     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0138-1     Document Type: Article

References (48)

1. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer. 1997;33 (6):907-11. (Pubitemid 27287045)
2. McMeekin DS. Sarcoma of the uterus. In: DiSaia G, editor. Clinical gynecologic oncology. 7th ed. Philadelphia: Mosby Elsevier; 2007. p. 185-200.
3. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12(6):687-90. (Pubitemid 35388035)
4. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003.
5. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204-8. (Pubitemid 38429571)
6. Kokawa K, Nishiyama K, Ikeuchi M, Ihara Y, Akamatsu N, Enomoto T, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer. 2006;16(3):1358-63. (Pubitemid 43886769)
7. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007;33(1):91-5. (Pubitemid 46156623)
8. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol. 2008;111(1):74-81.
9. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopatholog-ical and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355-64.
10. Wolfson AH, Wolfson DJ, Sittler SY, Breton L, Markoe AM, Schwade JG, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol. 1994;52(1):56-62. (Pubitemid 24066853)
11. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol. 2001;20(1):64-78. (Pubitemid 32042158)
12. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology. 2002;40(4):309-26. (Pubitemid 34595581)
13. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology. 2007;39(1):55-71.
14. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol. 2009;40(11):1571-85.
15. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology. 2001;39(3):273-8. (Pubitemid 34279662)
16. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131-9.
17. Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004;15;101 (6):1455-62. (Pubitemid 39180402)
18. Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99(1):36-42. (Pubitemid 41354580)
19. Poncelet C, Walker F, Madelenat P, Bringuier AF, Scoazec JY, Feldmann G, et al. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol. 2001;32 (11):1190-6. (Pubitemid 33104429)
20. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27(3):326-32.
21. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14(5):465-71. (Pubitemid 32448746)
22. Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochem-ical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92(1):71-9
23. International Federation of Gynecology and Obstetrics. Annual report of the results of treatment in gynaecological cancer. J Epidemiol Biostat. 2006;6.
24. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32(9):984-7. (Pubitemid 32911322)
25. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004;83(11):1085-8. (Pubitemid 39457489)
26. Kir G, Cetiner H, Karateke A, Gurbuz A, Bulbul D. Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas. Int J Gynecol Cancer. 2005;15(2):337-42. (Pubitemid 40396975)
27. Popiolek D,Yee H, Levine P, Vamvakas E, Demopoulos RI. MIB1 as a possible predictor of recurrence in low-grade endometrial stromal sarcoma of the uterus. Gynecol Oncol. 2003;90(2):353-7. (Pubitemid 36952026)
28. Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM. Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol. 1998;70(1):45-8. (Pubitemid 28368873)
29. Gokaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59(1):36-40. (Pubitemid 40082295)
30. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91(3):504-12. (Pubitemid 38388142)
31. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11(8):728-34. (Pubitemid 28381606)
32. Oliva E, Young RH, Amin MB, Clement PB. An immunohisto-chemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreac-tivity for individual antibodies. Am J Surg Pathol. 2002;26 (4):403-12. (Pubitemid 34280112)
33. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, et al. Uterine sarcomas express KIT protein but lack mutation (s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003;91(1):9-14. (Pubitemid 37188589)
34. Winter 3rd WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol. 2003;91(1):3-8. (Pubitemid 37188588)
35. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117(2):248-54
36. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46(7):1271-7.
37. Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, et al. CD44 expression in soft tissue sarcomas. Virchows Arch. 2000;436(6):574-8. (Pubitemid 30406640)
38. Ansink AC, Cross PA, Scorer P, de Barros LA, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (mixed Mullerian tumours): an immunohistochemical study. J Clin Pathol. 1997;50(4):328-31. (Pubitemid 27208253)
39. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466-71.
40. Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990;39(3):364-7.
41. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007;107 (3):513-7. (Pubitemid 350160866)
42. Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, et al. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet Gynecol. 2009;200(4):457. e1-5.
43. Lassus H, Butzow R. The classification of p53 immunohisto-chemical staining results and patient outcome in ovarian cancer. Br J Cancer. 2007;21;96(10):1621-2. author reply 1623-4. (Pubitemid 46762947)
44. Kim SH, Kim JW, Kim YT, Kim JH, Yoon BS, Ryu HS. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. Int J Gynaecol Obstet. 2006;95(3):272-7. (Pubitemid 44715894)
45. Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol. 1998;68(1):54-61. (Pubitemid 28109824)
46. Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Sabbatini P, et al. P53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer. 2006;16(2):849-53.
47. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol. 1999;75(3):432-6.
48. Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, et al. Prognostic factors in uterine carcinosarcoma: a clinicopath-ologic study of 25 patients. Cancer. 1998;1;82(3):512-9. (Pubitemid 28112990)